Mom’s Versus Dad’s BRCA

The age at which BRCA carriers are diagnosed with breast cancer may depend on which parent contributed the mutation.

Written byCristina Luiggi
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

STOCK.XCHNG, NGOULD

Whether a BRCA mutation is inherited from the mother or father may affect age of diagnosis or even the risk of developing cancer in the carrier, researchers presented at the San Antonio Breast Cancer Symposium last week. After analyzing 1,889 breast or ovarian cancer patients at the Monter Cancer Center in Lake Success, NY—130 of which knew the parent of origin of either their BRCA1 or BRCA2 mutation—the researchers found that the patients were diagnosed 6 to 9 years earlier if the mutation was passed down by the father.

“Genetic diseases may display parent-of-origin effects,” Iuliana Shapira, director of cancer genetics at the Monter Cancer Center said in a press release. “Cancer penetrance in mutations carriers may be determined by the parent origin of BRCA ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies